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ToxicityBackground and purpose: Radiotherapy is used to palliate pelvic symptoms of castration resistant prostate
cancer (CRPC). However, magnitude and time course of effects and toxicities are poorly documented.
Study aims were to evaluate changes in patient-reported target symptoms (TS), health-related quality
of life (HRQOL) and toxicity following palliative pelvic radiotherapy (PPRT) of CRPC.
Material and methods: 47 patients with CRPC and a symptomatic pelvic mass prescribed PPRT with 30–
39 Gy were prospectively included. Primary endpoint was patient-reported improvement or complete
resolution of the TS twelve weeks after PPRT. HRQOL changes were explored. Toxicity was
physician-evaluated.
Results: Lower urinary tract symptoms (LUTS) (45%), hematuria (26%) and pain (19%) were the most com-
mon TS. In the 40 evaluable patients, overall TS response twelve weeks after PPRT was 70%. TS responses
were 8/18 for LUTS, 11/12 for hematuria, and 7/9 for pain. Global HRQOL improved transiently. The most
common toxicity was grade 1 or 2 diarrhea (50%). There was no grade 4 toxicity.
Conclusions: In the majority of patients with CRPC and a symptomatic pelvic tumor, PPRT with 30–39 Gy
contributes to relief of hematuria, pain and other pelvic symptoms, with acceptable toxicity. Future stud-
ies should investigate whether PPRT regimens can be simpliﬁed.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 115 (2015) 314–320
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).In approximately 15–20% of patients with castration-resistant
prostate cancer (CRPC), growth of a pelvic tumor dominates the
clinical picture which is typiﬁed by micturition problems, pain,
hemorrhage, and obstruction of viscera and lymphatics [1]. In
these patients, palliative pelvic external beam radiotherapy
(PPRT) is often used although evidence regarding timing, duration
and magnitude of symptom relief and toxicity is deﬁcient. A recent
literature review indicates a trend toward positive effects yet there
is a need to prospectively document efﬁcacy for palliation of vari-
ous symptoms [2].
The lack of prospective studies in these patients, coupled with
heterogeneity and multiplicity of pelvic symptoms, meant that a
phase two study was the natural ﬁrst step in establishing an evi-
dence base for PPRT of CRPC. Research in palliative radiotherapy
presents several challenges including a high rate of attrition and
difﬁculty in measuring validated, well-deﬁned end-points in apopulation with rapidly declining health. Dedicated studies,
addressing the symptomatic effects of palliative radiotherapy are
therefore needed [3], and a pilot study has demonstrated feasibility
in this elderly population with prostate cancer, using
patient-reported outcomes [4]. The most appropriate fractionation
regimen for palliation of symptoms is uncertain and clinical prac-
tices therefore vary [2]. According to an informal survey of
Norwegian radiation oncologists, 30–39 Gray (Gy) in 3 Gy fractions
was most widely used at the start of the study.
The primary aim of the current study was to prospectively eval-
uate the palliative effect of PPRT in patients with CRPC and a symp-
tomatic pelvic tumor 12 weeks after the completion of PPRT.
Secondarily, we explored HRQOL, symptom status and toxicity at
the end of and six and 12 weeks after radiotherapy.
Methods
Study design and patients
Between November, 2009 and June, 2014, seven of nine radio-
therapy centers in Norway conducted this phase 2 study.
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soft-tissue pelvic mass (primary tumor, recurrence or metastasis
due to adenocarcinoma of the prostate), independent of the simul-
taneous presence of metastases. They had to be P18 years, with a
life expectancy greater than three months. Radiotherapy had to
have been prescribed in the range of 30–39 Gy in 3 Gy fractions
by referring physicians. Patients were ineligible if they were unable
to comply with study questionnaires, had started systemic anti-
neoplastic treatment within four weeks of baseline, or if this was
planned within six weeks after radiotherapy. Patients who had
previously been treated with pelvic radiotherapy, had a syn-
chronous pelvic cancer or other cancer requiring treatment were
ineligible, as were those receiving treatment with an investiga-
tional drug.Treatment
In order to limit heterogeneity, external beam radiotherapy was
delivered in 10–13 fractions of 3 Gy. Treatment planning was
preferably done by computerized tomography. Gross tumor vol-
ume (GTV) encompassed the prostate tumor, pathologically
enlarged lymph nodes, or a combination of these. Planning target
volume included the GTV and a margin of 1.0–2.0 cm. Field
set-up was at the discretion of the treating physician. There were
no limitations on the supportive interventions that could be given
during the study.Data collection
Four study visits were scheduled; at baseline (14–0 days prior
to radiotherapy), at the completion of radiotherapy (±3 days),
and six and twelve weeks (±7 days) after completion of treatment.
Background data pertaining to prostate cancer history were col-
lected from patient records. Ancillary palliative procedures and
medication use were documented. Survival data were obtained
from the Norwegian Cause of Death Registry.Baseline
N=47
End of treatment
N=47
6-week follow-up
N=44
Dead: n=3Symptom and toxicity assessment
Patients were asked at baseline to identify a ‘‘target symptom’’,
the chief pelvic complaint that they hoped the radiotherapy would
relieve. At each of the three follow-up visits they were asked to
describe the target symptom severity compared to baseline as
either ‘‘worse’’, ‘‘unchanged’’, ‘‘better’’ or ‘‘resolved’’. The two latter
alternatives, better or resolved, were regarded as ‘‘response’’.
To assess HRQOL and characterize pain the validated Norwegian
versions of the European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, version
3,0) [5,6] and Brief Pain Inventory short form, with body map
(BPI) [7,8] were used at each study visit. Questionnaires were
administered and collected at the radiotherapy centers.
Radiotherapists were responsible for ensuring that forms were
completed and they were available to assist the study participants,
as needed. In instances where patients were prevented from
attending study follow-up visits, an attempt was made to contact
them by telephone and administer the questionnaires via post.
Physicians prospectively graded pre-speciﬁed pelvic symptoms
and potential toxicities according to the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events (CTCAE
v.3.0) [9] criteria at each study visit.12-week follow-up
N=40
Dead: n=2
Progressive disease: n=2
Fig. 1. Inclusion and follow-up of patients.Statistical considerations
The primary endpoint was the proportion of patients reporting
improved or resolved target symptom severity compared to base-
line at the 12-week follow-up visit. Secondary endpoints werechanges in target symptom severity at the end of treatment and
at the 6-week follow up visit, as well as HRQOL and degree of tox-
icity at all of the follow-up study visits.
A target symptom response rate of at least 30–40% was deemed
clinically meaningful. If the true response rate is 40%, a total of 47
patients would be needed to obtain 90% power to exclude a
response rate of <20%, with signiﬁcance level of 5%.
Correspondingly, the power would be 80% with a total of 35
patients. With 40 evaluable patients the maximum length of a
95% conﬁdence interval for the proportion of responders is ±15%.
With regard to the secondary endpoint, a change ofP10 points
in the EORTC QLQ-C30 global QOL score is considered clinically sig-
niﬁcant [10]. Assuming a standard deviation in the range of 20–25
[11], 32–51 patients would give a power of 80%. Thus, a total of 40
evaluable patients were deemed sufﬁcient to detect relevant
effects on both primary and secondary outcomes.
Descriptive statistics were generated to describe the popula-
tion, treatment given, and the primary endpoint. 95% conﬁdence
intervals were also estimated. Results for the main target symptom
subgroups (lower urinary tract symptoms [12] (LUTS), macroscopic
hematuria, pain) are presented separately due to clinical relevance.
Differences in median HRQOL score from baseline to each
follow-up visit are assessed by the 2-tailed Wilcoxon signed rank
test (signiﬁcance level of p < 0.05) for paired data. Toxicity is pre-
sented in percent of patients with each grade of symptoms at the
four study visits. In order to describe the study population,
Kaplan–Meier survival analysis was performed with the observa-
tion time spanning from the start of radiotherapy to death or
through 2013.Ethical considerations
Study participants gave written informed consent. The study
was approved by the Regional Ethical Committee (ref. S-09080c
2009/1695) and the Privacy Protection Council in Norway (ref.
20940) and by hospital institutional boards. The study was regis-
tered on ClinicalTrials.gov (ref. NCT01023529).Results
Patient and treatment characteristics
Forty-seven patients were included and all completed the pre-
scribed radiotherapy (Fig. 1). Five patients died during the study
(three of prostate cancer, two of unrelated causes) and deteriorat-
ing general health of an additional two precluded their
Table 2
Palliative pelvic radiotherapy.
Radiotherapy delivered (n)*
27 Gy in 9 f 1
30 Gy in 10 f 19
36 Gy in 12 f 10
39 Gy in 13 f 17
Radiotherapy target (n)
Primary tumor 46
Pathological lymph nodes only 1
Primary tumor and pathological lymph nodes 10
Volume treated (90% target dose, in cm3)
Median (range) 737 (252–5500)
Treatment planning (n)
316 Palliative pelvic radiotherapy – prostate cancerparticipation to completion of the study. Forty patients were evalu-
able 12 weeks after PPRT.
The 47 included patients had a median age of 79 years and 34
had documented metastatic disease (Table 1). All patients had
undergone androgen deprivation therapy and eight had been given
prior chemotherapy. The median time since diagnosis was
68.5 months. The most frequent patient-reported target symptoms
were LUTS, macroscopic hematuria, and pain.
PPRT was delivered in 3 Gy fractions, to a mean total dose of
34.5 Gy (range 27–39 Gy) (Table 2). The irradiated volume varied
from 252 to 5500 cm3 (median 737 cm3). In the majority of
patients, radiotherapy was planned with three-dimensional com-
puted tomography and delivered conformally, with multiple ﬁelds.Conformal 3-dimensional CT plans 45
Conventional 2
Number of treatment ﬁelds
Median (range) 4 (2–9)
Gy = Gray; f = fractions; CT = computed tomography.
* Two patients did not complete the prescribed radiotherapy course (one due to
an infection and the other due to a fall resulting in a fracture).Symptom palliation
Of the 40 patients evaluable for target symptom severity
12 weeks after PPRT, 18 reported complete resolution, 10 improve-
ment, 10 unchanged severity and two reported worsening target
symptoms. Improvement or complete resolution of the target
symptom was achieved in 62% of the evaluable patients at the
end of radiotherapy, 80% after six weeks, and 70% after 12 weeks
(Table 3).Table 1
Patient characteristics at baseline (N = 47).
Parameter Value
Age (years)
Median (range) 79 (60–93)
ECOG performance status (n)
0 8
1 25
2 13
3 1
Patients with documented metastatic disease (n)
Total 34
Skeletal 24
Lymphnode 24
Time since diagnosis (months)
Median (range) 68.5 (9–214)
Laboratory values, median (range)
PSA (lg/L) 59 (1–2266)
Albumin (g/L) 40 (27–47)
Hemoglobin (g/dL) 12.1 (7.9–16.5)
Previous cancer treatment (n)
Prostatectomy 0
Orchiectomy 1
TURP 19
Chemotherapy 8
Androgen deprivation therapy 47
Patients’ target symptom (n)
LUTS 21
Hematuria 12
Pain 9
Rectal obstruction 3
Lower extremity/scrotal edema 2
Opiate analgesic use (n) 10
Anticholinergic use for bladder spasm (n) 5
Urinary tract intervention (n)
Nephrostomy 7
Ureteric stent 1
Suprapubic catheter 5
Permanent urethral catheter 6
Intermittent catheterization 2
LUTS = lower urinary tract symptoms (symptoms relating to storage and/or voiding
disturbance);
ECOG = Eastern Cooperative Oncology Group; TURP = transurethral resection of the
prostate;
PSA = prostate-speciﬁc antigen.According to intention to treat analysis, overall response rate
for all included patients (n = 47) after 12 weeks was 60% (28/47).
For the subgroups of patients with LUTS, macroscopic hematuria
and pain, response rates were 38%, 92% and 78%, respectively.
Eighty-seven percent (41/47) of all included patients reported
complete resolution or improvement of target symptom at at least
one of their follow-up visits.
The most consistent results were reported for palliation of
macroscopic hematuria (100% response after 12 weeks among
the 40 evaluable patients) while outcomes for patients with LUTS
were more variable. Variation of symptom severity over time for
individual patients in the main target symptom groups is schemat-
ically displayed in Fig. 2.
Compared to baseline, median global QOL score for patients that
remained in the study increased by 12.5 points (p = 0.032) at the
six-week follow-up. Clinically meaningful improvement was
reported by 16/41 (39%) of patients at the six-week follow-up
and 15/40 (38%) of patients at the 12-week follow-up (Table 3).Ancillary palliative interventions
Of the 21 patients that required bladder catheters, ureteric
stents, nephrostomies, or a combination of these at baseline
(Table 1), ﬁve had discontinued the intervention by the 12-week
follow-up. Six patients underwent urinary tract intervention (six
bladder catheter placements, one transurethral resection of the
prostate (TURP)) during the study period.
Although only nine patients identiﬁed pain as their target
symptom, 29 patients reported pain on the BPI at at least one study
visit. Of these, 20 (69%) referred to pelvic pain. Opioids were used
by 11/47 (23%) patients at baseline, 13/47 (28%) at the end of
radiotherapy, 7/44 (16%) at the six-week follow-up and 10/40
(25%) at the 12-week follow-up.
Two patients were given palliative radiotherapy of skeletal
metastases (hip, spine) during the study period. One patient was
given docetaxel ﬁve days prior to the 12-week follow-up visit.Toxicity
Transient mild to moderate diarrhea at the end of radiotherapy
was the most frequent toxicity seen (50%) (Fig. 3). Pelvic symptoms
in general improved during the study. There were no interruptions
or premature terminations of radiotherapy due to toxicity. There
were no grade 4 toxicities.
Table 3
Target symptom response and HRQOL compared to baseline.
Proportion of evaluable patients reporting target symptom severity improved or resolved (95% CI)
Number of patients with target symptom at baseline End of radiotherapy 6 week follow-up 12 week follow-up
LUTS n = 21 6/21 10/18 8/18
29% 56% 44%
(0.10–0.48) (0.33–0.79) (0.21–0.67)
Macroscopic hematuria n = 12 11/12 11/11 11/11
92% 100% 100%
(0.77–1.0)
Pelvic pain n = 9 8/9 9/9 7/9
89% 100% 78%
(0.69–1.0) (0.51–1.0)
Other# n = 5 4/5 3/3 2/2
80% 100% 100%
(0.45–1.0)
Total n = 47 29/47 33/41 28/40
62% 80% 70%
(0.48–0.76) (0.68–0.92) 0.56–0.84)
Global QOL compared to baseline Proportion of evaluable patients (95% CI)
End of radiotherapy 6 week follow-up 12 week follow-up
Clinically signiﬁcant improvement* 12/47 16/41 15/40
26% 39% 38%
(0.13–0.39) (0.24–0.51) (0.23–0.53)
Stable** 26/47 20/41 14/40
55% 49% 35%
(0.40–0.70) (0.33–0.65) (0.20–0.50)
Clinically signiﬁcant deterioration*** 9/47 5/41 11/40
19% 12% 28%
(0.08–0.30) (0.02–0.22) (0.14–0.42)
HRQOL: global health status score median (IQR); p-value¤
Baseline End of radiotherapy 6 week follow-up 12 week follow-up
Global QOL score 50.0 58.3 66.7 62.5
(33–67) (42–75) (50–83) (50–83)
n = 47 n = 47 n = 41 n = 40
p = 0.229 p = 0.032 p = 0.340
CI = conﬁdence interval; LUTS = lower urinary tract symptoms (symptoms relating to storage and/or voiding disturbance); HRQOL = health-
related quality of life; IQR = inter-quartile range.
# Edema, rectal obstruction.
* IncreaseP 10 points.
** Values within nine points of baseline score.
*** DecreaseP 10 points.
¤ Score compared to baseline.
M.G. Cameron et al. / Radiotherapy and Oncology 115 (2015) 314–320 317Survival
At the time of analysis, median duration of study follow-up was
40 months (range 11–60). Median overall survival among the
included patients was 20 months (range 1–55) from the time of
radiotherapy start.Discussion
This study demonstrates that in patients with CRPC, symptoms
resulting from an advanced pelvic tumor are well-palliated with
PPRT. However, response rate, degree of response, onset and dura-
bility of effect varied for the three major target symptom groups.
Macroscopic hematuria and pain responded rapidly and consis-
tently, with the majority of patients experiencing improvement
or complete resolution of their target symptom during the treat-
ment period. The palliative effect in the LUTS subgroup was less
frequent, of slower onset, and more variable than for the other tar-
get symptom subgroups.
The frequency, degree, and duration of side-effects in this study
appear acceptable. In fact, pelvic symptom burden decreased overthe course of the study (see Fig. 3), likely reﬂecting the fact that the
positive effect on the constellation of pelvic symptoms beyond
those deﬁned as the target symptom, outweighed toxicities of
treatment. This is also exhibited in the stability and transient
improvement in HRQOL in the three months after PPRT, despite
the patients having progressive prostate cancer and limited sur-
vival at treatment start.
Various systemic treatments of CRPC have been shown to
improve survival and health-related quality of life (HRQOL) in
patients with metastatic disease, although their effect on symp-
toms resulting from the pelvic primary tumor is largely unknown
[13–15], and no studies are available which document the effects
of PPRT on HRQOL [2]. The results of this study support ﬁndings
of the retrospective studies of PPRT of PC to date [2] and are con-
sistent with symptomatic effects reported for PPRT of other pelvic
malignancies such as bladder [16], cervical [17], and rectal [18]
cancers.
Prolonged local pelvic control and improved survival have been
shown in patients with non-metastatic CRPC selected for treat-
ment with higher doses of PPRT (40–55 Gy) [19]. The majority of
incurable patients selected for such treatment aiming to delay
Resolved
n=4 
Improved
n=4 
n=21 
n=12 
n=9 
Unchanged
n=9 
Worse
n=1 
LUTS
Baseline EoT
2-3 week
radiotherapy
6 w 12 w
HEMATURIA
Resolved
n=8 
Improved
n=3 
Unchanged
n=0 
Worse
n=0 
Baseline EoT
2-3 week
radiotherapy
6 w 12 w
PAIN
Resolved
n=5 
Improved
n=2 
Unchanged
n=1 
Worse
n=1 
Baseline EoT
2-3 week
radiotherapy
6 w 12 w
Fig. 2. Patient-reported target symptom severity over time compared with baseline for the three major target symptoms. EOT = end of treatment; w = week follow-up;
   = patients who did not complete the study.
318 Palliative pelvic radiotherapy – prostate cancer
010
20
30
40
50
60
70
80
90
%
Grade 1
Grade 2
Grade 3
0
10
20
30
40
50
60
70
80
90
%
Grade 1
Grade 2
Grade 3
          Urinary                Urinary               Urinary            Hematuria           Dysuria
retenon            frequency         inconnence
B   E   6  12B   E   6  12B   E   6  12 B   E   6  12 B   E   6  12
Diarrhea         Nausea       Conspaon       Anal Edema*
inconnence           
B   E   6  12 B   E   6  12 B   E   6  12 B   E   6  12 B   E   6  12
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symptoms reported. ⁄ = lower extremity or scrotal edema. B = baseline; E = end of treatment; 6 = 6-week follow-up; 12 = 12-week follow-up.
M.G. Cameron et al. / Radiotherapy and Oncology 115 (2015) 314–320 319negative outcomes, are asymptomatic [4,19]. Patients in the cur-
rent study were prescribed doses less than 40 Gy prior to study
entry, primarily due to their more advanced stages of disease in
need of palliation coupled with a more limited life-expectancy.
To our knowledge, this is the ﬁrst prospective study exploring
symptomatic effects of PPRT of CRPC, yielding information not only
about the magnitude, but also the onset and duration of effects and
toxicities. It is the ﬁrst study to make use of patient-reported out-
comes and prospective, active capture of the speciﬁc toxicities
associated with PPRT, in order to explore the risk–beneﬁt balance.
It was a multi-center study of relatively unselected and elderly
patients, and ﬁndings are therefore presumed generalizable.
Despite the modest number of included patients, it was sufﬁcient
to meet statistical goals. The study made use of modern conformal
radiotherapy techniques, a relatively limited range of doses, and
was standardized in terms of target volume deﬁnitions. However
there was a degree of heterogeneity both in total radiotherapy dose
and, due to variable tumor volumes, the volumes treated.Palliative care of cancer patients consists of a multidimensional,
interdisciplinary approach to patients with terminal disease, often
making use of several simultaneous interventions. As such, effects
of the interventions overlap and are difﬁcult to reliably separate.
This presents a challenge when attempting to study singular stan-
dardized interventions within the greater framework of palliative
care, as was done in the present study. Results therefore apply to
‘‘palliation which includes PPRT’’, rather than to the isolated effect
of PPRT.
Several patients underwent interventions during the study per-
iod that may have impacted on symptom severity. However, for
ethical reasons, no restrictions were placed on these ancillary
treatments. Randomization of participants to continued palliative
care, with or without PPRT could have reduced the inﬂuence of
these confounding factors. However, despite the scant research
base [2], there is some evidence and a strong clinical tradition for
the use of PPRT in this clinical context. We therefore deemed it
unethical to withhold PPRT from a control group.
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pelvic tumor the majority had skeletal metastases. Metastases
were largely left untreated during the approximately four-month
study period, and were therefore likely to progress, leading to
worsening symptoms and HRQOL. Although attempts were made
to limit confounding by non-pelvic symptoms, the study data could
not, for example, determine what speciﬁc location of pain caused
patients to alter their analgesic use. The anchor-based responses
to the question of target symptom severity are therefore better
indicators of the degree of pelvic pain than pain scores and amount
of analgesic used. By the same token, separation of toxicity result-
ing from the PPRT from symptoms of tumor progression was not
feasible and although low, treatment-related toxicity may there-
fore be overestimated.
So as not to overburden participants, the study did not require
longer duration of follow-up or more frequent symptom evaluation
or procedures. Symptom reassessment at only three ﬁxed time
points may have led to missing peaks of toxicity or transient
changes in symptoms, thereby misrepresenting the true course of
symptoms and side-effects. In addition, 12 weeks of follow-up
after PPRT is insufﬁcient to evaluate delayed or longer-term symp-
tom palliation, the need for repeated intervention and to explore
possible long-term side-effects. This is particularly important given
that the median survival from the time of PPRT was 20 months.
Palliative TURP is a treatment option for LUTS, although nearly
40% of patients with CRPC do not beneﬁt [20]. Symptomatic out-
comes of TURP in prostate cancer patients improve when preoper-
ative urodynamic testing selects for intervention only those
patients with manifest obstruction [21]. Due to the poorer
response rate among the subgroup of patients with LUTS in this
study, it may be worthwhile to examine the use of urodynamics
prior to PPRT, and to optimize medical treatment of bladder dys-
function in these patients.
Several patients with hematuria reported complete resolution
after a single fraction of 3 Gy (results not shown), while those with
LUTS tended to respond later. This raises the question of the appro-
priateness of different radiotherapy approaches for different target
symptoms and should be investigated in fractionation studies.
Lower total doses, hypofractionated or delivered as single fractions
of for example 8 Gy, and repeated as needed may be appropriate
for palliation of hematuria while higher doses requiring fractiona-
tion may be necessary to affect bladder outlet or lymphatic
obstruction, where tumor-shrinkage is thought to be necessary. If
the effects of and tolerance for lower doses or shorter courses of
radiotherapy can be demonstrated to be equivalent to those seen
with higher doses and longer regimens, as has been shown in
skeletal metastases from prostate cancer [22], then simpliﬁed
radiotherapy could improve patient convenience, conserve
resources and reduce treatment costs.
Conclusion
In patients with CRPC and a symptomatic pelvic mass, PPRT
with doses in the range of 30–39 Gy contributes to effective palli-
ation of macroscopic hematuria, pain and other pelvic symptoms.
The applied radiotherapy does not impart signiﬁcant toxicity.
To our knowledge, this is the only prospective study of PPRT of
patients with CRPC which reports symptom outcomes. It provides
data against which future studies can be compared and that may
serve as a basis for planning studies. The question of optimal radio-
therapy dose and fractionation scheme in this context remains
unanswered and the possibility of lower doses and simpler, shorter
treatments warrants investigation.Conﬂict of interest statement
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